Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

Abstract: The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC.

Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.

Abstract: A near eye display system having an image display panel, a prism assembly comprising a first and second element and a structure such as a eye wear glasses frame. The front and rear surfaces of the first and second elements are aligned and bonded to form the prism assembly. A partially-reflective coating is applied to the interface of the first and second elements to define a beam-splitter interface. The image display panel is disposed near an upper optical region such as a refracting surface of the first element. The lower edge of the second element opposite the beam-splitter interface is a coated reflective surface mirror. The display panel, the optical region and the optically reflective surface are configured to provide compactness and to avoid the break of symmetry. The system accommodates large inter pupil distance (IPD) variation and left/right eye scanning motion.

Abstract: The present embodiments relate to a measuring apparatus and an associated measurement method. The measuring apparatus is installed on a line and includes a sensing unit having a first and a second voltage divider for producing a first and a second measurement signal with a measurement transducer. The first and second measurement signals are each forwardable via a measurement line directly to a signal transducer. The signal transducer is supplied with power via a supply line by being switchably connected to the measurement transducer.

Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis B virus (HBV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection and/or HBV-associated disorder, e.g., chronic hepatitis B infection.

Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

Abstract: A safety module for an automation system including a communication interface, which is configured for a signal-transmitting connection to a communication system including an output interface, which is configured for a signal-transmitting connection to consumers, which can be attached downstream, and including a processing device which is connected to both interfaces and is configured for processing communication signals from the communication interface and for providing processing results as output signals at the output interface. The processing device is configured such that a safety-related output signal is provided at the output interface if a safety signal, which is contained in a communication signal, is present, and if at least two data records, which are respectively provided in a communication signal, are encoded differently and are directed at the processing device, conform with one another.

Abstract: A cleaning fabric wound on a roll (12) is used for cleaning printing cylinders (2, 3, 4) of a printing system (1). The cleaning fabric (13) includes a liquid absorbable material configured to be soaked with a cleaning liquid containing a polar additive configured to make the cleaning liquid polar. The roll (12) of cleaning fabric (13) is included in a cleaning cassette (10) which is movable between an idle position out of contact with the printing cylinders, and an active position in which the cleaning fabric (13) included in the cassette (10) is in contact with a printing cylinder to be cleaned.

Abstract: The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.

Abstract: A field bus module for the operation of actuators and/or sensors with at least one device interface for the connection of a sensor and/or actuator, with at least one field bus interface for connection to a field bus system, and with a processing device for receiving and processing and sending field bus telegrams and also for making available control commands, especially safety-oriented control commands, to the device interface depending on incoming field bus telegrams wherein the processing device is configured to process in different operating modes sensor data that can be made available at the device interface and/or field bus telegrams that can be made available at the field bus interface, wherein an operating mode memory is allocated to the processing device for the optional provision of one of at least two different operating mode data sets at the processing device depending on an incoming field bus telegram.

Abstract: The present disclosure relates generally to cleavable linkers and uses thereof.

Abstract: A method of evaluating image data representative of a display icon relative to reference data representative of a reference icon to determine whether the display icon matches the reference icon, the reference icon comprising at least first and second image regions which are distinct in image contrast from one another, the image data defining pixel values corresponding to pixels of the display icon, the method comprising: for each of a plurality of areas of the display icon, categorizing that area as corresponding to one or none of the image regions based on a comparison between the pixel value or values for that area and at least a plurality of pixel-value ranges defined in relation to the reference icon, the pixel-value ranges corresponding to respective said image regions and defined so as to ensure sufficient image contrast between areas categorized as corresponding to different said image regions; generating categorization information representative of the image data indicating how the plurality of areas

Abstract: The invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.

Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.

Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.

Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.

Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The sense strand of the dsRNA agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsRNA agent comprises at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2?-OMe modification, wherein said modified nucleotides are separated by 11 nucleotides in length. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.

Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The sense strand of the dsRNA agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsRNA agent comprises at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2?-OMe modification, wherein said modified nucleotides are separated by 11 nucleotides in length. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.